United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises

Impact · against what's priced in

Regencell Bioscience faces severe downward pressure as it contends with a DOJ trading investigation and high dilution risks. The lack of validated clinical progress renders the current valuation speculative and unsustainable.

RGC−0.90

No priced-in read yet

In context

The company is burdened by a DOJ trading investigation, significant shareholder dilution risk, and a lack of externally validated clinical progress for its TCM-based treatments.

Read from the article alone

• valuation
• RGC
• adhd
• autism
• bioscience
• dilution
• doj investigation
• strong sell
• tcm

Search tags